Richard Price

List of Publications by Year
in descending order

329	18,741	13099	17105
papers	citations	68 h-index	122 g-index

343	343	343	10923
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Efficacy of Single-Dose Primaquine With Artemisinin Combination Therapy on Plasmodium falciparum Gametocytes and Transmission: An Individual Patient Meta-Analysis. Journal of Infectious Diseases, 2022, 225, 1215-1226.	4.0	22
2	Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet Infectious Diseases, The, 2022, 22, 367-376.	9.1	21
3	Tafenoquine for children: a step towards implementation. The Lancet Child and Adolescent Health, 2022, 6, 72-73.	5.6	2
4	Adults with Plasmodium falciparum malaria have higher magnitude and quality of circulating T-follicular helper cells compared to children. EBioMedicine, 2022, 75, 103784.	6.1	6
5	A fluorometric assay to determine the protective effect of glucose-6-phosphate dehydrogenase (G6PD) against a Plasmodium spp. infection in females heterozygous for the G6PD gene: proof of concept in Plasmodium falciparum. BMC Research Notes, 2022, 15, 76.	1.4	2
6	Identifying Targets of Protective Antibodies against Severe Malaria in Papua, Indonesia, Using Locally Expressed Domains of Plasmodium falciparum Erythrocyte Membrane Protein 1. Infection and Immunity, 2022, 90, IAI0043521.	2.2	3
7	Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Neglected Tropical Diseases, 2022, 16, e0010174.	3.0	14
8	Temporal distribution of Plasmodium falciparum recrudescence following artemisinin-based combination therapy: an individual participant data meta-analysis. Malaria Journal, 2022, 21, 106.	2.3	1
9	Haematological consequences of acute uncomplicated falciparum malaria: a WorldWide Antimalarial Resistance Network pooled analysis of individual patient data. BMC Medicine, 2022, 20, 85.	5.5	9
10	Delayed Diagnosis of Whippleâ€™s Disease Complicated by Jarischâ€“Herxheimer Reaction to Ceftriaxone Treatment: A Case Report and Literature Review. Tropical Medicine and Infectious Disease, 2022, 7, 40.	2.3	0
11	Malaria eradication revisited. International Journal of Epidemiology, 2022, 51, 382-392.	1.9	3
12	Cooperation in Countering Artemisinin Resistance in Africa: Learning from COVID-19. American Journal of Tropical Medicine and Hygiene, 2022, , .	1.4	2
13	Field evaluation of the diagnostic performance of EasyScan GO: a digital malaria microscopy device based on machine-learning. Malaria Journal, 2022, 21, 122.	2.3	15
14	Molecular profiling reveals features of clinical immunity and immunosuppression in asymptomatic P. falciparum malaria. Molecular Systems Biology, 2022, 18, e10824.	7.2	9
15	Variation in Glucose-6-Phosphate Dehydrogenase activity following acute malaria. PLoS Neglected Tropical Diseases, 2022, 16, e0010406.	3.0	8
16	Reducing the risk of Plasmodium vivax after falciparum infections in co-endemic areasâ€”a randomized controlled trial (PRIMA). Trials, 2022, 23, 416.	1.6	2
17	Geographical distribution and genetic diversity of Plasmodium vivax reticulocyte binding protein 1a correlates with patient antigenicity. PLoS Neglected Tropical Diseases, 2022, 16, e0010492.	3.0	2
18	Intermittent screening and treatment for malaria complementary to routine immunisation in the first year of life in Papua, Indonesia: a cluster randomised superiority trial. BMC Medicine, 2022, 20, .	5.5	0

#	Article	IF	Citations
19	Heterogeneity in prevalence of subclinical Plasmodium falciparum and Plasmodium vivax infections but no parasite genomic clustering in the Chittagong Hill Tracts, Bangladesh. Malaria Journal, 2022, 21, .	2.3	2
20	Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	10
21	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	97
22	Glucose-6-phosphate dehydrogenase activity in individuals with and without malaria: Analysis of clinical trial, cross-sectional and caseâ€“control data from Bangladesh. PLoS Medicine, 2021, 18, e1003576.	8.4	10
23	The changing epidemiology of Plasmodium vivax: Insights from conventional and novel surveillance tools. PLoS Medicine, 2021, 18, e1003560.	8.4	28
24	Spaceâ€“Time Clustering Characteristics of Malaria in Bhutan at the End Stages of Elimination. International Journal of Environmental Research and Public Health, 2021, 18, 5553.	2.6	4
25	Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study. PLoS Medicine, 2021, 18, e1003632.	8.4	60
26	Development and Validation of an In Silico Decision Tool To Guide Optimization of Intravenous Artesunate Dosing Regimens for Severe Falciparum Malaria Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
27	Hidden Biomass of Intact Malaria Parasites in the Human Spleen. New England Journal of Medicine, 2021, 384, 2067-2069.	27.0	82
28	Implementing radical cure diagnostics for malaria: user perspectives on G6PD testing in Bangladesh. Malaria Journal, 2021, 20, 217.	2.3	12
29	Bold measures to accelerate malaria elimination. Lancet Infectious Diseases, The, 2021, 21, 1480-1481.	9.1	1
30	Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study. PLoS Medicine, 2021, 18, e1003614.	8.4	15
31	High-dimensional mass cytometry identifies T cell and B cell signatures predicting reduced risk of Plasmodium vivax malaria. JCI Insight, 2021, 6, .	5.0	6
32	The Darwin Prospective Melioidosis Study: a 30-year prospective, observational investigation. Lancet Infectious Diseases, The, 2021, 21, 1737-1746.	9.1	58
33	The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance. Science Translational Medicine, 2021, 13, .	12.4	25
34	An open dataset of Plasmodium falciparum genome variation in 7,000 worldwide samples. Wellcome Open Research, 2021, 6, 42.	1.8	51
35	Longitudinal ex vivo and molecular trends of chloroquine and piperaquine activity against Plasmodium falciparum and P. vivax before and after introduction of artemisinin-based combination therapy in Papua, Indonesia. International Journal for Parasitology: Drugs and Drug Resistance, 2021, 17, 46-56.	3.4	4
36	Opening the policy blackbox: unravelling the process for changing national diagnostic and treatment guidelines for vivax malaria in seven countries. Malaria Journal, 2021, 20, 428.	2.3	7

#	Article	IF	Citations
37	Diagnostic Practices and Treatment for P. vivax in the InterEthnic Therapeutic Encounter of South-Central Vietnam: A Mixed-Methods Study. Pathogens, 2021, 10, 26.	2.8	4
38	Implementing parasite genotyping into national surveillance frameworks: feedback from control programmes and researchers in the Asiaâ€“Pacific region. Malaria Journal, 2020, 19, 271.	2.3	31
39	Identifying and combating the impacts of COVID-19 on malaria. BMC Medicine, 2020, 18, 239.	5.5	84
40	Primaquine for Plasmodium vivax malaria treatment â€“ Authors' reply. Lancet, The, 2020, 395, 1972.	13.7	0
41	Towards harmonization of microscopy methods for malaria clinical research studies. Malaria Journal, 2020, 19, 324.	2.3	13
42	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. PLoS Neglected Tropical Diseases, 2020, 14, e0008697.	3.0	8
43	A population of CD4 hi CD38 hi T cells correlates with disease severity in patients with acute malaria. Clinical and Translational Immunology, 2020, 9, e1209.	3.8	3
44	Precarity at the Margins of Malaria Control in the Chittagong Hill Tracts in Bangladesh: A Mixed-Methods Study. Pathogens, 2020, 9, 840.	2.8	5
45	Plasmodium vivax in the Era of the Shrinking P. falciparum Map. Trends in Parasitology, 2020, 36, 560-570.	3.3	135
46	Molecular surveillance over 14 years confirms reduction of Plasmodium vivax and falciparum transmission after implementation of Artemisinin-based combination therapy in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008295.	3.0	9
47	Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Medicine, 2020, 17, e1003084.	8.4	31
48	Factors affecting the electrocardiographic QT interval in malaria: A systematic review and meta-analysis of individual patient data. PLoS Medicine, 2020, 17, e1003040.	8.4	20
49	Transcriptional profiling and immunophenotyping show sustained activation of blood monocytes in subpatent Plasmodium falciparum infection. Clinical and Translational Immunology, 2020, 9, e1144.	3.8	13
50	Disseminating clinical study results to trial participants in Ethiopia: insights and lessons learned. Malaria Journal, 2020, 19, 205.	2.3	2
51	Genetic diversity and neutral selection in Plasmodium vivax erythrocyte binding protein correlates with patient antigenicity. PLoS Neglected Tropical Diseases, 2020, 14, e0008202.	3.0	5
52	The risk of morbidity and mortality following recurrent malaria in Papua, Indonesia: a retrospective cohort study. BMC Medicine, 2020, 18, 28.	5.5	47
53	Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6 <scp>PD</scp> deficiency. Medical Journal of Australia, 2020, 212, 152.	1.7	25
54	Malaria-related hospitalization during childhood in Papua, Indonesia: A retrospective cohort study. PLoS ONE, 2020, 15, e0228018.	2.5	3

#	Article	IF	Citations
55	Baseline results of a living systematic review for COVID-19 clinical trial registrations. Wellcome Open Research, 2020, 5, 116.	1.8	26
56	The risk of Plasmodium vivax parasitaemia after P. falciparum malaria: An individual patient data meta-analysis from the WorldWide Antimalarial Resistance Network. PLoS Medicine, 2020, 17, e1003393.	8.4	32
57	The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2020, 14, e0008838.	3.0	10
58	Multi-locus genotyping reveals established endemicity of a geographically distinct Plasmodium vivax population in Mauritania, West Africa. PLoS Neglected Tropical Diseases, 2020, 14, e0008945.	3.0	7
59	Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathogens, 2020, 16, e1009133.	4.7	81
60	The WorldWide Antimalarial Resistance Network Clinical Trials Publication Library: A Live, Open-Access Database of Plasmodium Treatment Efficacy Trials. American Journal of Tropical Medicine and Hygiene, 2020, 103, 359-368.	1.4	10
61	Cost-Effectiveness Analysis of Sex-Stratified Plasmodium vivax Treatment Strategies Using Available G6PD Diagnostics to Accelerate Access to Radical Cure. American Journal of Tropical Medicine and Hygiene, 2020, 103, 394-403.	1.4	11
62	Estimating the Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Review and Meta-Analysis. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1094-1099.	1.4	77
63	Neurosyphilis: Still prevalent and overlooked in an at risk population. PLoS ONE, 2020, 15, e0238617.	2.5	7
64	Title is missing!. , 2020, 17, e1003084.		0
65	Title is missing!. , 2020, 17, e1003084.		0
66	Title is missing!. , 2020, 17, e1003084.		0
67	Title is missing!. , 2020, 17, e1003084.		0
68	Title is missing!. , 2020, 17, e1003084.		0
69	Title is missing!. , 2020, 17, e1003393.		0
70	Title is missing!. , 2020, 17, e1003393.		0
71	Title is missing!. , 2020, 17, e1003393.		0
72	Title is missing!. , 2020, 17, e1003393.		0

#	Article	IF	Citations
73	Title is missing!. , 2020, 17, e1003393.		0
74	Title is missing!. , 2020, 14, e0008295.		0
75	Title is missing!. , 2020, 14, e0008295.		0
76	Title is missing!. , 2020, 14, e0008295.		0
77	Title is missing!. , 2020, 14, e0008295.		0
78	Title is missing!. , 2020, 14, e0008295.		0
79	Title is missing!. , 2020, 14, e0008945.		0
80	Title is missing!. , 2020, 14, e0008945.		0
81	Title is missing!. , 2020, 14, e0008945.		0
82	Title is missing!. , 2020, 14, e0008945.		0
83	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
84	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
85	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
86	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
87	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
88	Wide range of G6PD activities found among ethnic groups of the Chittagong Hill Tracts, Bangladesh. , 2020, 14, e0008697.		0
89	Title is missing!. , 2020, 14, e0008202.		0
90	Title is missing!. , 2020, 14, e0008202.		0

#	Article	IF	Citations
91	Title is missing!. , 2020, 14, e0008202.		0
92	Title is missing!. , 2020, 14, e0008202.		0
93	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
94	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
95	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
96	Neurosyphilis: Still prevalent and overlooked in an at risk population. , 2020, 15, e0238617.		0
97	Title is missing!. , 2020, 16, e1009133.		0
98	Title is missing!. , 2020, 16, e1009133.		0
99	Title is missing!. , 2020, 16, e1009133.		0
100	Title is missing!. , 2020, 16, e1009133.		0
101	High Risk of Plasmodium vivax Malaria Following Splenectomy in Papua, Indonesia. Clinical Infectious Diseases, 2019, 68, 51-60.	5.8	11
102	The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis. BMC Medicine, 2019, 17, 151.	5.5	34
103	Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet, The, 2019, 394, 929-938.	13.7	106
104	Malaria morbidity and mortality following introduction of a universal policy of artemisinin-based treatment for malaria in Papua, Indonesia: A longitudinal surveillance study. PLoS Medicine, 2019, 16, e1002815.	8.4	38
105	Analysis of erroneous data entries in paper based and electronic data collection. BMC Research Notes, 2019, 12, 537.	1.4	8
106	Early and late mortality after malaria in young children in Papua, Indonesia. BMC Infectious Diseases, 2019, 19, 922.	2.9	18
107	The efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine with and without primaquine on Plasmodium vivax recurrence: A systematic review and individual patient data meta-analysis. PLoS Medicine, 2019, 16, e1002928.	8.4	27
108	Genomic Analysis of Plasmodium vivax in Southern Ethiopia Reveals Selective Pressures in Multiple Parasite Mechanisms. Journal of Infectious Diseases, 2019, 220, 1738-1749.	4.0	50

#	Article	IF	Citations
109	Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000â€“17: a spatial and temporal modelling study. Lancet, The, 2019, 394, 332-343.	13.7	276
110	Evaluating antimalarial efficacy in single-armed and comparative drug trials using competing risk survival analysis: a simulation study. BMC Medical Research Methodology, 2019, 19, 107.	3.1	5
111	Safety of primaquine in infants with Plasmodium vivax malaria in Papua, Indonesia. Malaria Journal, 2019, 18, 111.	2.3	7
112	3,3â€²-Disubstituted 5,5â€²-Bi(1,2,4-triazine) Derivatives with Potent in Vitro and in Vivo Antimalarial Activity. Journal of Medicinal Chemistry, 2019, 62, 2485-2498.	6.4	16
113	Glycocalyx Breakdown Is Associated With Severe Disease and Fatal Outcome in Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2019, 69, 1712-1720.	5.8	31
114	Dealing with indeterminate outcomes in antimalarial drug efficacy trials: a comparison between complete case analysis, multiple imputation and inverse probability weighting. BMC Medical Research Methodology, 2019, 19, 215.	3.1	3
115	Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: AAsystematic review and meta-analysis. PLoS Medicine, 2019, 16, e1002992.	8.4	37
116	Circulating Neutrophil Extracellular Traps and Neutrophil Activation Are Increased in Proportion to Disease Severity in Human Malaria. Journal of Infectious Diseases, 2019, 219, 1994-2004.	4.0	46
117	Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2019, 19, 91-101.	9.1	56
118	Plasmodium falciparum Activates CD16+ Dendritic Cells to Produce Tumor Necrosis Factor and Interleukin-10 in Subpatent Malaria. Journal of Infectious Diseases, 2019, 219, 660-671.	4.0	17
119	Growing evidence of Plasmodium vivax across malaria-endemic Africa. PLoS Neglected Tropical Diseases, 2019, 13, e0007140.	3.0	135
120	Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data. Bulletin of the World Health Organization, 2019, 97, 828-836.	3.3	7
121	Title is missing!. , 2019, 16, e1002992.		0
122	Title is missing!. , 2019, 16, e1002992.		0
123	Title is missing!. , 2019, 16, e1002992.		0
124	Title is missing!. , 2019, 16, e1002992.		0
125	Drugs that reduce transmission of falciparum malaria. Lancet Infectious Diseases, The, 2018, 18, 585-586.	9.1	3
126	The ethics of using placebo in randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial. BMC Medical Ethics, 2018, 19, 19.	2.4	8

#	Article	IF	Citations
127	Expanding the Use of Primaquine for the Radical Cure of Plasmodium vivax. Clinical Infectious Diseases, 2018, 67, 1008-1009.	5.8	6
128	Artemether-Lumefantrine Versus Chloroquine for the Treatment of Uncomplicated Plasmodium knowlesi Malaria: An Open-Label Randomized Controlled Trial CAN KNOW. Clinical Infectious Diseases, 2018, 66, 229-236.	5.8	26
129	Loss of complement regulatory proteins on uninfected erythrocytes in vivax and falciparum malaria anemia. JCI Insight, 2018, 3, .	5.0	20
130	Plasmodium falciparum artemisinin resistance monitoring in Sabah, Malaysia: in vivo therapeutic efficacy and kelch13 molecular marker surveillance. Malaria Journal, 2018, 17, 463.	2.3	8
131	Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation. BMC Research Notes, 2018, 11, 855.	1.4	14
132	Field evaluation of quantitative point of care diagnostics to measure glucose-6-phosphate dehydrogenase activity. PLoS ONE, 2018, 13, e0206331.	2.5	50
133	Investigating the Efficacy of Triple Artemisinin-Based Combination Therapies for Treating Plasmodium falciparum Malaria Patients Using Mathematical Modeling. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	43
134	Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model. Malaria Journal, 2018, 17, 279.	2.3	26
135	UCT943, a Next-Generation Plasmodium falciparum PI4K Inhibitor Preclinical Candidate for the Treatment of Malaria. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	40
136	Genomic analysis of a pre-elimination Malaysian Plasmodium vivax population reveals selective pressures and changing transmission dynamics. Nature Communications, 2018, 9, 2585.	12.8	59
137	The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient pooled meta-analysis. Lancet Infectious Diseases, The, 2018, 18, 1025-1034.	9.1	85
138	Platelets kill circulating parasites of all major Plasmodium species in human malaria. Blood, 2018, 132, 1332-1344.	1.4	85
139	Low risk of recurrence following artesunateâ€“Sulphadoxineâ€“pyrimethamine plus primaquine for uncomplicated Plasmodium falciparum and Plasmodium vivax infections in the Republic of the Sudan. Malaria Journal, 2018, 17, 117.	2.3	5
140	The Plasmodium falciparum transcriptome in severe malaria reveals altered expression of genes involved in important processes including surface antigenâ€“encoding var genes. PLoS Biology, 2018, 16, e2004328.	5.6	67
141	Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis. PLoS Medicine, 2018, 15, e1002579.	8.4	47
142	Therapeutic Response to Dihydroartemisininâ€“Piperaquine for P. falciparum and P. vivax Nine Years after Its Introduction in Southern Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 677-682.	1.4	23
143	Treatment-Seeking Behavior after the Implementation of a Unified Policy of Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Malaria in Papua, Indonesia. American Journal of Tropical Medicine and Hygiene, 2018, 98, 543-550.	1.4	17
144	Malaria Elimination: Time to Target All Species. American Journal of Tropical Medicine and Hygiene, 2018, 99, 17-23.	1.4	62

#	Article	IF	Citations
145	Plasmodium malariae and P. ovale genomes provide insights into malaria parasite evolution. Nature, 2017, 542, 101-104.	27.8	150
146	Plasmodium falciparum and Plasmodium vivax Demonstrate Contrasting Chloroquine Resistance Reversal Phenotypes. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	7
147	A tetraoxane-based antimalarial drug candidate that overcomes PfK13-C580Y dependent artemisinin resistance. Nature Communications, 2017, 8, 15159.	12.8	51
148	Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group. Malaria Journal, 2017, 16, 141.	2.3	52
149	Adverse effects of mefloquine for the treatment of uncomplicated malaria in Thailand: A pooled analysis of 19, 850 individual patients. PLoS ONE, 2017, 12, e0168780.	2.5	26
150	Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis. PLoS Neglected Tropical Diseases, 2017, 11, e0005602.	3.0	15
151	Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow. Malaria Journal, 2017, 16, 281.	2.3	24
152	Barriers to routine G6PD testing prior to treatment with primaquine. Malaria Journal, 2017, 16, 329.	2.3	19
153	Molecular analysis demonstrates high prevalence of chloroquine resistance but no evidence of artemisinin resistance in Plasmodium falciparum in the Chittagong Hill Tracts of Bangladesh. Malaria Journal, 2017, 16, 335.	2.3	12
154	Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malaria Journal, 2017, 16, 361.	2.3	43
155	Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated Plasmodium falciparum malaria: pitfalls and challenges. Malaria Journal, 2017, 16, 430.	2.3	14
156	Genomic Characterization of RecrudescentPlasmodium malariaeafter Treatment with Artemether/Lumefantrine. Emerging Infectious Diseases, 2017, 23, 1300-1307.	4.3	36
157	Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLoS Medicine, 2017, 14, e1002212.	8.4	50
158	Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial. PLoS Medicine, 2017, 14, e1002299.	8.4	64
159	Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: A hospital-based cohort study. PLoS Medicine, 2017, 14, e1002379.	8.4	74
160	VivaxGEN: An open access platform for comparative analysis of short tandem repeat genotyping data in Plasmodium vivax populations. PLoS Neglected Tropical Diseases, 2017, 11, e0005465.	3.0	13
161	A Comparison of Three Quantitative Methods to Estimate G6PD Activity in the Chittagong Hill Tracts, Bangladesh. PLoS ONE, 2017, 12, e0169930.	2.5	34
162	Genetic micro-epidemiology of malaria in Papua Indonesia: Extensive P. vivax diversity and a distinct subpopulation of asymptomatic P. falciparum infections. PLoS ONE, 2017, 12, e0177445.	2.5	16

#	Article	IF	Citations
163	Passively versus Actively Detected Malaria: Similar Genetic Diversity but Different Complexity of Infection. American Journal of Tropical Medicine and Hygiene, 2017, 97, 1788-1796.	1.4	16
164	Treatment-seeking behaviour and associated costs for malaria in Papua, Indonesia. Malaria Journal, 2016, 15, 536.	2.3	35
165	Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan. Malaria Journal, 2016, 15, 277.	2.3	21
166	Characterization of blood dendritic and regulatory T cells in asymptomatic adults with sub-microscopic Plasmodium falciparum or Plasmodium vivax infection. Malaria Journal, 2016, 15, 328.	2.3	12
167	â€œAsymptomaticâ€•Malaria: A Chronic and Debilitating Infection That Should Be Treated. PLoS Medicine, 2016, 13, e1001942.	8.4	259
168	Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Doseâ€“Efficacy Modeling. PLoS Medicine, 2016, 13, e1002138.	8.4	35
169	Nocardiosis in the Tropical Northern Territory of Australia, 1997â€“2014. Open Forum Infectious Diseases, 2016, 3, ofw208.	0.9	32
170	Efficacy of Artesunate-mefloquine for Chloroquine-resistantPlasmodium vivaxMalaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clinical Infectious Diseases, 2016, 62, 1403-1411.	5.8	44
171	Type I Interferons Regulate Immune Responses in Humans with Blood-Stage Plasmodium falciparum Infection. Cell Reports, 2016, 17, 399-412.	6.4	88
172	Diagnosis and Treatment of Plasmodium vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2016, 95, 35-51.	1.4	65
173	A Triazolopyrimidine-Based Dihydroorotate Dehydrogenase Inhibitor with Improved Drug-like Properties for Treatment and Prevention of Malaria. ACS Infectious Diseases, 2016, 2, 945-957.	3.8	71
174	Genomic Analysis Reveals a Common Breakpoint in Amplifications of thePlasmodium vivaxMultidrug Resistance 1 Locus in Thailand. Journal of Infectious Diseases, 2016, 214, 1235-1242.	4.0	29
175	Optimal health and disease management using spatial uncertainty: a geographic characterization of emergent artemisinin-resistant Plasmodium falciparum distributions in Southeast Asia. International Journal of Health Geographics, 2016, 15, 37.	2.5	13
176	Differences in PfEMP1s recognized by antibodies from patients with uncomplicated or severe malaria. Malaria Journal, 2016, 15, 258.	2.3	23
177	Plasmodium vivax infection: a major determinant of severe anaemia in infancy. Malaria Journal, 2016, 15, 321.	2.3	23
178	Genomic analysis of local variation and recent evolution in Plasmodium vivax. Nature Genetics, 2016, 48, 959-964.	21.4	169
179	Performance and user acceptance of the Bhutan febrile and malaria information system: report from a pilot study. Malaria Journal, 2016, 15, 52.	2.3	4
180	Analysis of ex vivo drug response data of Plasmodium clinical isolates: the pros and cons of different computer programs and online platforms. Malaria Journal, 2016, 15, 137.	2.3	12

#	Article	IF	Citations
181	Expression of Plasmodium vivax crt-o Is Related to Parasite Stage but Not Ex Vivo Chloroquine Susceptibility. Antimicrobial Agents and Chemotherapy, 2016, 60, 361-367.	3.2	25
182	Artesunateâ€“mefloquine versus chloroquine for treatment of uncomplicated Plasmodium knowlesi malaria in Malaysia (ACT KNOW): an open-label, randomised controlled trial. Lancet Infectious Diseases, The, 2016, 16, 180-188.	9.1	58
183	A new Plasmodium vivax reference sequence with improved assembly of the subtelomeres reveals an abundance of pir genes. Wellcome Open Research, 2016, 1, 4.	1.8	118
184	Further Evidence of Increasing Diversity of Plasmodium vivax in the Republic of Korea in Recent Years. PLoS ONE, 2016, 11, e0151514.	2.5	13
185	G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study. PLoS ONE, 2016, 11, e0154015.	2.5	28
186	Asymptomatic Vivax and Falciparum Parasitaemia with Helminth Co-Infection: Major Risk Factors for Anaemia in Early Life. PLoS ONE, 2016, 11, e0160917.	2.5	16
187	Submicroscopic and Asymptomatic Plasmodium Parasitaemia Associated with Significant Risk of Anaemia in Papua, Indonesia. PLoS ONE, 2016, 11, e0165340.	2.5	48
188	Molecular Epidemiology of P. vivax in Iran: High Diversity and Complex Sub-Structure Using Neutral Markers, but No Evidence of Y976F Mutation at pvmdr1. PLoS ONE, 2016, 11, e0166124.	2.5	17
189	High burden of diabetic foot infections in the top end of Australia: An emerging health crisis (DEFINE) Tj ETQq1 1 0.784314 rgBT /Ove	2.8	47
190	Baseline data of parasite clearance in patients with falciparum malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malaria Journal, 2015, 14, 359.	2.3	47
191	Clinical determinants of early parasitological response to ACTs in African patients with uncomplicated falciparum malaria: a literature review and meta-analysis of individual patient data. BMC Medicine, 2015, 13, 212.	5.5	61
192	Treatment policy change to dihydroartemisininâ€“piperaquine contributes to the reduction of adverse maternal and pregnancy outcomes. Malaria Journal, 2015, 14, 272.	2.3	13
193	A systematic review of sub-microscopic Plasmodium vivax infection. Malaria Journal, 2015, 14, 360.	2.3	63
194	Quantification of Plasmodium ex vivo drug susceptibility by flow cytometry. Malaria Journal, 2015, 14, 417.	2.3	14
195	Targeting vivax malaria in the Asia Pacific: The Asia Pacific Malaria Elimination Network Vivax Working Group. Malaria Journal, 2015, 14, 484.	2.3	22
196	Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia. Malaria Journal, 2015, 14, 525.	2.3	26
197	The challenges of introducing routine G6PD testing into radical cure: a workshop report. Malaria Journal, 2015, 14, 377.	2.3	51
198	Defining the relationship between Plasmodium vivax parasite rate and clinical disease. Malaria Journal, 2015, 14, 191.	2.3	12

#	Article	IF	Citations
199	Severe Malarial Thrombocytopenia: A Risk Factor for Mortality in Papua, Indonesia. Journal of Infectious Diseases, 2015, 211, 623-634.	4.0	55
200	The effect of dose on the antimalarial efficacy of artemetherâ€“lumefantrine: a systematic review and pooled analysis of individual patient data. Lancet Infectious Diseases, The, 2015, 15, 692-702.	9.1	74
201	The clinical implications of thrombocytopenia in adults with severe falciparum malaria: a retrospective analysis. BMC Medicine, 2015, 13, 97.	5.5	36
202	Contrasting Transmission Dynamics of Co-endemic Plasmodium vivax and P. falciparum: Implications for Malaria Control and Elimination. PLoS Neglected Tropical Diseases, 2015, 9, e0003739.	3.0	63
203	A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature, 2015, 522, 315-320.	27.8	353
204	Global extent of chloroquine-resistant Plasmodium vivax â€“ Authors' reply. Lancet Infectious Diseases, The, 2015, 15, 630-631.	9.1	2
205	Potent Ex Vivo Activity of Naphthoquine and Methylene Blue against Drug-Resistant Clinical Isolates of Plasmodium falciparum and Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2015, 59, 6117-6124.	3.2	20
206	Preserved Dendritic Cell HLA-DR Expression and Reduced Regulatory T Cell Activation in Asymptomatic Plasmodium falciparum and P. vivax Infection. Infection and Immunity, 2015, 83, 3224-3232.	2.2	27
207	Parasite Biomass-Related Inflammation, Endothelial Activation, Microvascular Dysfunction and Disease Severity in Vivax Malaria. PLoS Pathogens, 2015, 11, e1004558.	4.7	120
208	Impaired Systemic Tetrahydrobiopterin Bioavailability and Increased Dihydrobiopterin in Adult Falciparum Malaria: Association with Disease Severity, Impaired Microvascular Function and Increased Endothelial Activation. PLoS Pathogens, 2015, 11, e1004667.	4.7	33
209	The effect of dosing strategies on the therapeutic efficacy of artesunate-amodiaquine for uncomplicated malaria: a meta-analysis of individual patient data. BMC Medicine, 2015, 13, 66.	5.5	37
210	Malaria eradication and elimination: views on how to translate a vision into reality. BMC Medicine, 2015, 13, 167.	5.5	101
211	Contrasting Ex Vivo Efficacies of â€œReversed Chloroquineâ€•Compounds in Chloroquine-Resistant Plasmodium falciparum and P. vivax Isolates. Antimicrobial Agents and Chemotherapy, 2015, 59, 5721-5726.	3.2	12
212	Plasmodium malariae Infection Associated with a High Burden of Anemia: A Hospital-Based Surveillance Study. PLoS Neglected Tropical Diseases, 2015, 9, e0004195.	3.0	71
213	Variation in Complexity of Infection and Transmission Stability between Neighbouring Populations of Plasmodium vivax in Southern Ethiopia. PLoS ONE, 2015, 10, e0140780.	2.5	33
214	Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infectious Diseases, The, 2014, 14, 982-991.	9.1	300
215	Assessment of therapeutic responses to gametocytocidal drugs in Plasmodium falciparum malaria. Malaria Journal, 2014, 13, 483.	2.3	61
216	Decreased Endothelial Nitric Oxide Bioavailability, Impaired Microvascular Function, and Increased Tissue Oxygen Consumption in Children with Falciparum Malaria. Journal of Infectious Diseases, 2014, 210, 1627-1632.	4.0	38

#	Article	IF	Citations
217	KAF156 Is an Antimalarial Clinical Candidate with Potential for Use in Prophylaxis, Treatment, and Prevention of Disease Transmission. Antimicrobial Agents and Chemotherapy, 2014, 58, 5060-5067.	3.2	122
218	Polymorphisms in Plasmodium falciparum Chloroquine Resistance Transporter and Multidrug Resistance 1 Genes: Parasite Risk Factors That Affect Treatment Outcomes for P. falciparum Malaria After Artemether-Lumefantrine and Artesunate-Amodiaquine. American Journal of Tropical Medicine and Hygiene, 2014, 91, 833-843.	1.4	204
219	Pyrazoleamide compounds are potent antimalarials that target Na+ homeostasis in intraerythrocytic Plasmodium falciparum. Nature Communications, 2014, 5, 5521.	12.8	108
220	Mortality attributable to Plasmodium vivaxmalaria: a clinical audit from Papua, Indonesia. BMC Medicine, 2014, 12, 217.	5.5	80
221	Detection of Mycobacterium leprae by PCR Testing of Sputa from a Patient with Pulmonary Cryptococcus Coinfection in Northern Australia. Journal of Clinical Microbiology, 2014, 52, 3811-3812.	3.9	4
222	Single-dose radical cure of Plasmodium vivax : a step closer. Lancet, The, 2014, 383, 1020-1021.	13.7	18
223	Genetic diversity and population structure of Plasmodium vivax in Central China. Malaria Journal, 2014, 13, 262.	2.3	22
224	Making the Most of Clinical Data: Reviewing the Role of Pharmacokinetic-Pharmacodynamic Models of Anti-malarial Drugs. AAPS Journal, 2014, 16, 962-974.	4.4	26
225	Improving the Radical Cure of Plasmodium vivax Malaria. American Journal of Tropical Medicine and Hygiene, 2014, 91, 3-4.	1.4	5
226	A study protocol for a randomised open-label clinical trial of artesunate-mefloquine versus chloroquine in patients with non-severe Plasmodium knowlesi malaria in Sabah, Malaysia (ACT KNOW) Tj ETQq0 0 0 rgBT /Overlock 10 T	1.9	10
227	Dihydroartemisinin-Piperaquine Treatment of Multidrug Resistant Falciparum and Vivax Malaria in Pregnancy. PLoS ONE, 2014, 9, e84976.	2.5	37
228	Rapid Clinical Assessment to Facilitate the Triage of Adults with Falciparum Malaria, a Retrospective Analysis. PLoS ONE, 2014, 9, e87020.	2.5	18
229	Early parasitological response following artemisinin-containing regimens: a critical review of the literature. Malaria Journal, 2013, 12, 125.	2.3	33
230	Preface. Advances in Parasitology, 2013, 81, xi-xii.	3.2	1
231	A robust design for identification of the Parasite Clearance Estimator. Malaria Journal, 2013, 12, 410.	2.3	9
232	Impaired Skeletal Muscle Microvascular Function and Increased Skeletal Muscle Oxygen Consumption in Severe Falciparum Malaria. Journal of Infectious Diseases, 2013, 207, 528-536.	4.0	42
233	Quinolone-3-Diarylethers: A New Class of Antimalarial Drug. Science Translational Medicine, 2013, 5, 177ra37.	12.4	187
234	Potential of Artemisinin-Based Combination Therapies to Block Malaria Transmission. Journal of Infectious Diseases, 2013, 207, 1627-1629.	4.0	10

#	Article	IF	Citations
235	Increased Carboxyhemoglobin in Adult Falciparum Malaria is Associated With Disease Severity and Mortality. Journal of Infectious Diseases, 2013, 208, 813-817.	4.0	11
236	Impaired Pulmonary Nitric Oxide Bioavailability in Pulmonary Tuberculosis: Association With Disease Severity and Delayed Mycobacterial Clearance With Treatment. Journal of Infectious Diseases, 2013, 208, 616-626.	4.0	29
237	Major Burden of Severe Anemia from Non-Falciparum Malaria Species in Southern Papua: A Hospital-Based Surveillance Study. PLoS Medicine, 2013, 10, e1001575.	8.4	117
238	Gametocyte Dynamics and the Role of Drugs in Reducing the Transmission Potential of Plasmodium vivax. Journal of Infectious Diseases, 2013, 208, 801-812.	4.0	43
239	L-arginine and Vitamin D Adjunctive Therapies in Pulmonary Tuberculosis: A Randomised, Double-Blind, Placebo-Controlled Trial. PLoS ONE, 2013, 8, e70032.	2.5	93
240	Effective Preparation of Plasmodium vivax Field Isolates for High-Throughput Whole Genome Sequencing. PLoS ONE, 2013, 8, e53160.	2.5	26
241	A Randomized Pilot Study of L-Arginine Infusion in Severe Falciparum Malaria: Preliminary Safety, Efficacy and Pharmacokinetics. PLoS ONE, 2013, 8, e69587.	2.5	42
242	Plasmodium vivax Population Structure and Transmission Dynamics in Sabah Malaysia. PLoS ONE, 2013, 8, e82553.	2.5	45
243	Nonlinear Mixed-Effects Modelling of In Vitro Drug Susceptibility and Molecular Correlates of Multidrug Resistant Plasmodium falciparum. PLoS ONE, 2013, 8, e69505.	2.5	5
244	An Analytical Method for Assessing Stage-Specific Drug Activity in Plasmodium vivax Malaria: Implications for Ex Vivo Drug Susceptibility Testing. PLoS Neglected Tropical Diseases, 2012, 6, e1772.	3.0	23
245	A Long Neglected World Malaria Map: Plasmodium vivax Endemicity in 2010. PLoS Neglected Tropical Diseases, 2012, 6, e1814.	3.0	448
246	Preface. Advances in Parasitology, 2012, 80, ix-x.	3.2	0
247	Monitoring antimalarial drug resistance: Applying lessons learned from the past in a fast-moving present. International Journal for Parasitology: Drugs and Drug Resistance, 2012, 2, 126-133.	3.4	20
248	Plasmodium vivax. Advances in Parasitology, 2012, 80, 151-201.	3.2	178
249	Diagnosis and Treatment of Plasmodium vivax Malaria. Advances in Parasitology, 2012, 80, 203-270.	3.2	62
250	Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax. Trends in Parasitology, 2012, 28, 522-529.	3.3	70
251	The Global Public Health Significance of Plasmodium vivax. Advances in Parasitology, 2012, 80, 1-111.	3.2	105
252	Assessing the utility of an anti-malarial pharmacokinetic-pharmacodynamic model for aiding drug clinical development. Malaria Journal, 2012, 11, 303.	2.3	42

#	Article	IF	Citations
253	Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malaria Journal, 2012, 11, 280.	2.3	155
254	The anaemia of Plasmodium vivax malaria. Malaria Journal, 2012, 11, 135.	2.3	173
255	Chemotherapeutic Strategies for Reducing Transmission of Plasmodium vivax Malaria. Advances in Parasitology, 2012, 80, 271-300.	3.2	28
256	Comparative Ex Vivo Activity of Novel Endoperoxides in Multidrug-Resistant Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2012, 56, 5258-5263.	3.2	38
257	Ex VivoActivity of Histone Deacetylase Inhibitors against Multidrug-Resistant Clinical Isolates ofPlasmodium falciparumandP. vivax. Antimicrobial Agents and Chemotherapy, 2011, 55, 961-966.	3.2	53
258	Trends in malaria research in 11 Asian Pacific countries: an analysis of peer-reviewed publications over two decades. Malaria Journal, 2011, 10, 131.	2.3	7
259	Considerations on the use of nucleic acid-based amplification for malaria parasite detection. Malaria Journal, 2011, 10, 323.	2.3	34
260	Plasmodium vivax Recurrence Following Falciparum and Mixed Species Malaria: Risk Factors and Effect of Antimalarial Kinetics. Clinical Infectious Diseases, 2011, 52, 612-620.	5.8	124
261	Plasmodium vivax treatments. Current Opinion in Infectious Diseases, 2011, 24, 578-585.	3.1	44
262	Differential Cellular Recognition of Antigens During Acute Plasmodium falciparum and Plasmodium vivax Malaria. Journal of Infectious Diseases, 2011, 203, 1192-1199.	4.0	7
263	In VivoandIn VitroEfficacy of Chloroquine againstPlasmodium malariaeandP. ovalein Papua, Indonesia. Antimicrobial Agents and Chemotherapy, 2011, 55, 197-202.	3.2	26
264	Ex Vivo Drug Susceptibility of Ferroquine against Chloroquine-Resistant Isolates of Plasmodium falciparum and P. vivax. Antimicrobial Agents and Chemotherapy, 2011, 55, 4461-4464.	3.2	37
265	Dihydroartemisinin-Piperaquine Versus Chloroquine in the Treatment of Plasmodium vivax Malaria in Thailand: A Randomized Controlled Trial. Clinical Infectious Diseases, 2011, 53, 977-984.	5.8	71
266	Highly Effective Therapy for Maternal Malaria Associated With a Lower Risk of Vertical Transmission. Journal of Infectious Diseases, 2011, 204, 1613-1619.	4.0	36
267	Coma Associated with Microscopy-Diagnosed Plasmodium vivax: A Prospective Study in Papua, Indonesia. PLoS Neglected Tropical Diseases, 2011, 5, e1032.	3.0	44
268	The burden and treatment of HIV in tuberculosis patients in Papua Province, Indonesia: a prospective observational study. BMC Infectious Diseases, 2010, 10, 362.	2.9	22
269	Greater Endothelial Activation, Weibelâ€Palade Body Release and Host Inflammatory Response toPlasmodium vivax,Compared withPlasmodium falciparum: A Prospective Study in Papua, Indonesia. Journal of Infectious Diseases, 2010, 202, 109-112.	4.0	60
270	In Vivo Parasitological Measures of Artemisinin Susceptibility. Journal of Infectious Diseases, 2010, 201, 570-579.	4.0	133

#	Article	IF	Citations
271	Inferred relatedness and heritability in malaria parasites. Proceedings of the Royal Society B: Biological Sciences, 2010, 277, 2531-2540.	2.6	41
272	In Vitro Activity of Pyronaridine against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2010, 54, 5146-5150.	3.2	36
273	Ageâ€Related Susceptibility to Severe Malaria Associated with Galectinâ€2 in Highland Papuans. Journal of Infectious Diseases, 2010, 202, 117-124.	4.0	13
274	Severe Congenital Malaria Acquired in utero. American Journal of Tropical Medicine and Hygiene, 2010, 82, 563-565.	1.4	30
275	A Simple Score to Predict the Outcome of Severe Malaria in Adults. Clinical Infectious Diseases, 2010, 50, 679-685.	5.8	89
276	Increased Asymmetric Dimethylarginine in Severe Falciparum Malaria: Association with Impaired Nitric Oxide Bioavailability and Fatal Outcome. PLoS Pathogens, 2010, 6, e1000868.	4.7	70
277	Artemisinin combination therapy for vivax malaria. Lancet Infectious Diseases, The, 2010, 10, 405-416.	9.1	204
278	Maximising the public health benefit of antimalarials. Lancet Infectious Diseases, The, 2010, 10, 654-655.	9.1	4
279	A study of the TNF/LTA/LTB locus and susceptibility to severe malaria in highland papuan children and adults. Malaria Journal, 2010, 9, 302.	2.3	13
280	Relationship of Cellâ€Free Hemoglobin to Impaired Endothelial Nitric Oxide Bioavailability and Perfusion in Severe Falciparum Malaria. Journal of Infectious Diseases, 2009, 200, 1522-1529.	4.0	124
281	Artemisinin Combination Therapy for Malaria: Beyond Good Efficacy. Clinical Infectious Diseases, 2009, 49, 1638-1640.	5.8	22
282	Antimalarial Therapies in Children from Papua New Guinea. New England Journal of Medicine, 2009, 360, 1254-1255.	27.0	13
283	In Vivo and In Vitro Efficacy of Amodiaquine Monotherapy for Treatment of Infection by Chloroquine-Resistant Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2009, 53, 1094-1099.	3.2	22
284	Parasite-Dependent Expansion of TNF Receptor IIâ€“Positive Regulatory T Cells with Enhanced Suppressive Activity in Adults with Severe Malaria. PLoS Pathogens, 2009, 5, e1000402.	4.7	118
285	High Deformability ofPlasmodium vivaxâ€“Infected Red Blood Cells under Microfluidic Conditions. Journal of Infectious Diseases, 2009, 199, 445-450.	4.0	107
286	New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance. Current Opinion in Infectious Diseases, 2009, 22, 430-435.	3.1	300
287	Vivax Malaria: A Major Cause of Morbidity in Early Infancy. Clinical Infectious Diseases, 2009, 48, 1704-1712.	5.8	147
288	The pathophysiology of vivax malaria. Trends in Parasitology, 2009, 25, 220-227.	3.3	347

#	Article	IF	Citations
289	Towards optimal design of anti-malarial pharmacokinetic studies. Malaria Journal, 2009, 8, 189.	2.3	14
290	Human T cell recognition of the blood stage antigen Plasmodium hypoxanthine guanine xanthine phosphoribosyl transferase (HGXPRT) in acute malaria. Malaria Journal, 2009, 8, 122.	2.3	10
291	A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malaria Journal, 2009, 8, 89.	2.3	204
292	The effect of varying analytical methods on estimates of anti-malarial clinical efficacy. Malaria Journal, 2009, 8, 77.	2.3	8
293	Changes in the Treatment Responses to Artesunate-Mefloquine on the Northwestern Border of Thailand during 13 Years of Continuous Deployment. PLoS ONE, 2009, 4, e4551.	2.5	212
294	Simplified antimalarial therapeutic monitoring: using the day-7 drug level?. Trends in Parasitology, 2008, 24, 159-163.	3.3	76
295	Plasmodium falciparum gametocyte dynamics in areas of different malaria endemicity. Malaria Journal, 2008, 7, 249.	2.3	74
296	Plasmodium vivax trophozoites insensitive to chloroquine. Malaria Journal, 2008, 7, 94.	2.3	55
297	Antibodies toPlasmodium falciparumandPlasmodium vivaxMerozoite Surface Protein 5 in Indonesia: Speciesâ€Specific and Crossâ€Reactive Responses. Journal of Infectious Diseases, 2008, 198, 134-142.	4.0	65
298	Stronger Activity of Human Immunodeficiency Virus Type 1 Protease Inhibitors against Clinical Isolates of Plasmodium vivax than against Those of P. falciparum. Antimicrobial Agents and Chemotherapy, 2008, 52, 2435-2441.	3.2	34
299	Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax. Antimicrobial Agents and Chemotherapy, 2008, 52, 1040-1045.	3.2	119
300	Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17097-17102.	7.1	235
301	The Relationship between Age and the Manifestations of and Mortality Associated with Severe Malaria. Clinical Infectious Diseases, 2008, 47, 151-157.	5.8	214
302	Pharmacokinetics of <scp>l</scp> -Arginine in Adults with Moderately Severe Malaria. Antimicrobial Agents and Chemotherapy, 2008, 52, 4381-4387.	3.2	33
303	Adverse Pregnancy Outcomes in an Area Where Multidrugâ€ResistantPlasmodium vivaxandPlasmodium falciparumInfections Are Endemic. Clinical Infectious Diseases, 2008, 46, 1374-1381.	5.8	131
304	Recovery of Endothelial Function in Severe Falciparum Malaria: Relationship with Improvement in Plasma<scp>l</scp>â€Arginine and Blood Lactate Concentrations. Journal of Infectious Diseases, 2008, 198, 602-608.	4.0	73
305	Multidrug-Resistant Plasmodium vivax Associated with Severe and Fatal Malaria: A Prospective Study in Papua, Indonesia. PLoS Medicine, 2008, 5, e128.	8.4	510
306	Safety Profile of L-Arginine Infusion in Moderately Severe Falciparum Malaria. PLoS ONE, 2008, 3, e2347.	2.5	28

#	Article	IF	Citations
307	Improving Case Definitions for Severe Malaria. PLoS Medicine, 2007, 4, e267.	8.4	28
308	Dihydroartemisinin-Piperaquine versus Artesunate-Amodiaquine: Superior Efficacy and Posttreatment Prophylaxis against Multidrug-Resistant Plasmodium falciparum and Plasmodium vivax Malaria. Clinical Infectious Diseases, 2007, 44, 1067-1074.	5.8	129
309	Clinical and Pharmacological Determinants of the Therapeutic Response to Dihydroartemisinin-Piperaquine for Drug-Resistant Malaria. Antimicrobial Agents and Chemotherapy, 2007, 51, 4090-4097.	3.2	81
310	Impaired nitric oxide bioavailability and <scp>l</scp>-arginineâ€“reversible endothelial dysfunction in adults with falciparum malaria. Journal of Experimental Medicine, 2007, 204, 2693-2704.	8.5	270
311	Lung Injury in Vivax Malaria: Pathophysiological Evidence for Pulmonary Vascular Sequestration and Posttreatment Alveolarâ€Capillary Inflammation. Journal of Infectious Diseases, 2007, 195, 589-596.	4.0	172
312	Two fixed-dose artemisinin combinations for drug-resistant falciparum and vivax malaria in Papua, Indonesia: an open-label randomised comparison. Lancet, The, 2007, 369, 757-765.	13.7	237
313	Comparison of three molecular methods for the detection and speciation of Plasmodium vivax and Plasmodium falciparum. Malaria Journal, 2007, 6, 124.	2.3	64
314	World Antimalarial Resistance Network (WARN) III: Molecular markers for drug resistant malaria. Malaria Journal, 2007, 6, 121.	2.3	99
315	World Antimalarial Resistance Network I: Clinical efficacy of antimalarial drugs. Malaria Journal, 2007, 6, 119.	2.3	57
316	Intrahost Selection ofPlasmodium falciparum pfmdr1Alleles after Antimalarial Treatment on the Northwestern Border of Thailand. Journal of Infectious Diseases, 2007, 195, 134-141.	4.0	42
317	Chloroquine Resistant Plasmodium vivax: In Vitro Characterisation and Association with Molecular Polymorphisms. PLoS ONE, 2007, 2, e1089.	2.5	187
318	Electrocardiographic Safety Evaluation of Dihydroartemisininâ€“Piperaquine in the Treatment of Uncomplicated falciparum Malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-450.	1.4	41
319	Vivax Malaria: Neglected and Not Benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	675
320	Vivax malaria: neglected and not benign. American Journal of Tropical Medicine and Hygiene, 2007, 77, 79-87.	1.4	445
321	Electrocardiographic safety evaluation of dihydroartemisinin piperaquine in the treatment of uncomplicated falciparum malaria. American Journal of Tropical Medicine and Hygiene, 2007, 77, 447-50.	1.4	32
322	Improving the availability of artesunate for treatment of severe malaria. Medical Journal of Australia, 2006, 184, 3-4.	1.7	9
323	Molecular and Pharmacological Determinants of the Therapeutic Response to Artemether-Lumefantrine in Multidrug-Resistant Plasmodium falciparum Malaria. Clinical Infectious Diseases, 2006, 42, 1570-1577.	5.8	258
324	Lung Injury in Uncomplicated and Severe Falciparum Malaria: A Longitudinal Study in Papua, Indonesia. Journal of Infectious Diseases, 2005, 192, 1966-1974.	4.0	74

#	Article	IF	Citations
325	Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet, The, 2005, 366, 717-725.	13.7	973
326	Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet, The, 2004, 364, 438-447.	13.7	707
327	Mefloquine Pharmacokinetic-Pharmacodynamic Models: Implications for Dosing and Resistance. Antimicrobial Agents and Chemotherapy, 2000, 44, 3414-3424.	3.2	112
328	Artemisinin drugs: novel antimalarial agents. Expert Opinion on Investigational Drugs, 2000, 9, 1815-1827.	4.1	97
329	An open dataset of Plasmodium vivax genome variation in 1,895 worldwide samples. Wellcome Open Research, 0, 7, 136.	1.8	16